DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Nov 13, 2024
- Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation
- Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET
Read more at prnewswire.com
